DEPARTAMENTO DE
MEDICAMENTOS
VETERINARIOS

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

FINAL PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

NEOSKILAB 1.5 mg/ml solution for injection for cattle, sheep, goats and horses

CORREO ELECTRÓNICO

mresvet@aemps.es

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443

MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0389/001/DC
Name, strength and pharmaceutical form	NEOSKILAB 1.5 mg/ml solution for injection for cattle, sheep, goats and horses (ES,CY, EE,HU,HR, IE, IT, LT,LV, PT, BE, EL, LU, RO) NEOSKILAB solution for injection for cattle, sheep, goats and horses (FR)
Applicant	Labiana Life Sciences, S.A. Venus, 26. 08228 Terrassa (Barcelona) Spain
Active substance(s)	Neostigmine metilsulfate
ATC vet code	QN07AA01
Target species	Cattle, sheep, goats and horses.
Indication for use	Cattle, sheep and goats: - Ruminal atony - Intestinal atony Horses: - Intestinal atony - Bladder atony

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (http://www.hma.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) Generic application of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	Day 210 (DCP): 03/03/2021 Day 90 (First RUP): 20/10/2021
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	CY, EE, FR, HR, HU, IE, IT, LT, LV, PT, BE, EL, LU, RO.

I. SCIENTIFIC OVERVIEW

This was a generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended. Neoskilab 1.5 mg/ml solution for injection is the generic veterinary medicinal product and contains Neostigmine metilsulfate as active substance. The reference product is Rumintral authorised in Spain since 1994.

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 1.5 mg/ml of neostigmine metilsulfate as active substance and methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives. Other ingredients are propylene glycol, sodium chloride and water for injections.

The container/closure system is an amber 25 ml glass vial, closed with a rubber-chlorobutyl septum and an aluminium capsule

The choice of the formulation and the presence of preservative are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is neostigmine metilsulfate, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data and/or certificates of suitability issued by the EDQM have been provided and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site<s> have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of safety tests are not required.

The safety and residues aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users and consumers.

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of pharmacological studies are not required.

Toxicological Studies

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, results of toxicological studies are not required.

User Safety

As this is a generic application according to Article 13(1), and bioequivalence with a reference product has been demonstrated, no different risk for the user is foreseen and the warnings and safety measures of the reference product are applicable.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will be used to treat a small number of animals in a flock or herd.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted because this application is for a generic product, submitted in accordance with Article 13(1) of Directive 2001/82/EC, and bioequivalence with the reference product has been demonstrated.

MRLs

Neostigmine is listed in table 1 of the Annex to Commission Regulation (EU) No 37/2010:

Pharmacologically active substance(s)	Marker residue	Animal species	MRLs (µg/kg)	Target tissues	Other provisions
neostigmine	NOT APPLICABLE	All food producing species	No MRL required	NOT APPLICABLE	NO ENTRY

The excipients are classified as follows:

Excipient	Status
Methyl Parahydroxybenzoate	Included in table 1 of Commission Regulation (EU) No 37/2010 – No MRL required. Food additive E-218.
Propyl Parahydroxybenzoate	Included in table 1 of Commission Regulation (EU) No 37/2010 – No MRL required.
Sodium chloride	Included in table 1 of Commission Regulation (EU) No 37/2010 – No MRL required.
Propylene glycol	Included in table 1 of Commission Regulation (EU) No 37/2010 – No MRL required.
Purified water	Included in "out of scope" list

Withdrawal Periods

The same withdrawal periods than the reference products are proposed:
Meat and offal: Zero days.
Milk: Zero hours

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies(pharmaceuticals only)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, pharmacodynamics, pharmacokinetics and tolerance studies are not required. The efficacy claims for this product are equivalent to those of the reference product

IV.B Clinical Studies (pharmaceuticals and immunologicals)

As this is a generic application according to Article 13.1, and bioequivalence with a reference product has been demonstrated, clinical studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None